05:40 PM EDT, 10/07/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that it has discontinued the SunRISe-2 clinical study of TAR-200 in patients with muscle-invasive bladder cancer as the drug did not show superiority compared to chemoradiation.

The company was evaluating TAR-200 in combination with Cetrelimab versus concurrent chemoradiotherapy in patients with muscle-invasive bladder cancer who are not receiving radical cystectomy, a surgical process to remove the bladder and nearby tissues.

The study was discontinued following a recommendation by an independent data monitoring committee, the company said.

Price: 159.01, Change: -0.52, Percent Change: -0.33